Back
Keros Therapeutics Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
60
KROS
Keros Therapeutics
Last Price:
60.76
Seasonality Move:
38.45%
Sell
41
ALNY
Alnylam Pharmaceuticals
Last Price:
285.72
Seasonality Move:
13.96%
Buy
60
Keros Therapeutics (KROS)
is a Buy
Is Keros Therapeutics a Buy, Sell or Hold?
- The current Keros Therapeutics [KROS] share price is $60.14. The Score for KROS is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
- KROS is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
41
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $284.69. The Score for ALNY is 41, which is 18% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
KROS Stock Price Chart
What is Keros Therapeutics's stock price today?
-
The Keros Therapeutics share price today is $60.14
The current trend is moderately bullish and KROS is experiencing slight buying pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $284.69
The current trend is moderately bullish and ALNY is experiencing slight buying pressure.
KROS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.25 | Buy |
| Relative Strength Index (14 RSI): | 55.64 | Buy |
| Chaikin Money Flow: | 82977 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (57.66 - 61.04) | Buy |
| Bollinger Bands (100): | (45.18 - 57.08) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 5.22 | Buy |
| Relative Strength Index (14 RSI): | 52.21 | Buy |
| Chaikin Money Flow: | 18297 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (270.92 - 291.12) | Buy |
| Bollinger Bands (100): | (215.05 - 289.81) | Buy |
KROS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 60.01 | Buy |
| 20-day SMA: | 60.01 | Buy |
| 50-day SMA: | 55.19 | Buy |
| 200-day SMA: | 54.89 | Buy |
| 8-day EMA: | 60.09 | Buy |
| 20-day EMA: | 59.3 | Buy |
| 50-day EMA: | 56.32 | Buy |
| 200-day EMA: | 51.82 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 291.18 | Sell |
| 20-day SMA: | 282.87 | Buy |
| 50-day SMA: | 274.65 | Buy |
| 200-day SMA: | 204.43 | Buy |
| 8-day EMA: | 288.3 | Sell |
| 20-day EMA: | 284.33 | Buy |
| 50-day EMA: | 272.82 | Buy |
| 200-day EMA: | 225.29 | Buy |
Keros Therapeutics Earnings Growth & KROS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.04 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.28 per share, and a decrease next year of $0.49 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.77 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.32 per share, and an increase next year of $0.75 per share.
Keros Therapeutics Technical Analysis
| Oct 15 | Oct 16 | Oct 18 | Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 15 | 16 | 18 | 21 | 22 | 23 | 24 | 25 | 28 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Oct 15 | Oct 16 | Oct 18 | Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 15 | 16 | 18 | 21 | 22 | 23 | 24 | 25 | 28 | 29 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||